An Update on the Use of 5-Alpha-Reductase Inhibitors

The document provided an update on the use of 5alpha-reductase inhibitors, which were used primarily for the treatment of conditions like benign prostatic hyperplasia and androgenetic alopecia. These inhibitors worked by blocking the conversion of testosterone to dihydrotestosterone (DHT), a hormone linked to hair loss and prostate growth. The review discussed the efficacy and safety profiles of these drugs, highlighting their role in reducing symptoms and slowing disease progression. It also addressed potential side effects, such as sexual dysfunction, and emphasized the importance of patient selection and monitoring during treatment.